Royal Marsden Hospital NHS Trust
Also known as: EORTC Trial Co-Chair, Royal Marden Hospital, Sutton, UK | he Institute of Cancer Research, Royal Marsden NHS Foundation Trust | ICR/Royal Marsden | Institute of Cancer Research and Royal Marsden Hospital | Institute of Cancer Research, Royal Marsden Hospital | Institute of Cancer Research, Royal Marsden NHS Foundation Trust | MRCP FRCR | National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK | Royal London Hospital | Royal Marsden Foundation Trust Institute of Cancer Research | Royal Marsden Hospital - Chelsea, London, UK | Royal Marsden Hospital - Drug Development Unit | Royal Marsden Hospital Foundation Trust | Royal Marsden Hospital/Institute of Cancer Research | Royal Marsden Hospital London | Royal Marsden Hospital, London | Royal Marsden Hospital, London, UK | Royal Marsden Hospital NHS Foundation Trust | Royal Marsden Hospital NHS- Institute of Cancer Research | Royal Marsden Hospital, Surrey, UK | Royal Marsden Hospital, Sutton, Surrey, England, SM2 5PT | Royal Marsden Hospital Trust, London, UK | Royal Marsden Hospital, UK | Royal Marsden NHS Foundation | Royal Marsden NHS Foundation Trust | Royal Marsden NHS Foundation Trust, Surrey, Uinted Kingdom | Royal Marsden, UK | Royal Marsdon Hospital/Institute for Cancer Research | Royla Marsden NHS Foundation Trust | The Institute of Cancer Research, Royal Marsden NHS Foundation Trust | The Institute of Cancer Research, Royal Marsden NHS Foundation Trust London United Kingdom | The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust | The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust | The Institute of Cancer Research/The Royal Marsden NHSFT | The Royal Marsden | The Royal Marsden Hospital | The Royal Marsden Hospital, London | The Royal Marsden Hospital, London & Surrey, UK | The Royal Marsden Hospital, London, UK | The Royal Marsden Hospital NHS Foundation Trust | The Royal Marsden Hospital, Sutton, UK | The Royal Marsden Hospital, UK | The Royal Marsden NHS Foundation Trust and Imperial College London | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research | The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT | The Royal Marsden, UK
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1993Last known activity
Jan 31, 2026
Timeline
1940s
- Jan 1, 1948
Royal Marsden Hospital NHS Trust— Founded
Drugs by trial phase (182 distinct, 190 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (69 own, 0 via acquisition)
Phase 2 (82 own, 0 via acquisition)
Phase 1 (25 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Anus Neoplasms
- Brain Neoplasms
- Breakthrough Pain
- Breast Neoplasms
- Carcinoma
- Carcinoma, Lobular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Central Nervous System Neoplasms
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Digestive System Neoplasms
- Endometrial Neoplasms
- Enteropathy-Associated T-Cell Lymphoma
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Fallopian Tube Neoplasms
- Fibrosis
- Gastrointestinal Neoplasms
- Glioma
- Head and Neck Neoplasms
- Histiocytoma, Malignant Fibrous
- Immunoblastic Lymphadenopathy
- Infections
- Kidney Neoplasms
- Laryngeal Neoplasms
- Leiomyosarcoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Long Term Adverse Effects
- Lung Neoplasms
- Lymphedema
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Medulloblastoma
- Melanoma
- Mesothelioma
- Microsatellite Instability
- Mucositis
- Multiple Myeloma
- Myelodysplastic Syndromes
- Nausea
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Nervous System Neoplasms
- Neuroblastoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pathologic Processes
- Pelvic Neoplasms
- Peripheral Nervous System Diseases
- Pneumonia
- Postoperative Complications
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Radiation Pneumonitis
- Rectal Neoplasms
- Recurrence
- Rhabdomyosarcoma
- Salivary Gland Neoplasms
- Sarcoma
- Sarcoma, Alveolar Soft Part
- Seminoma
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Stomatitis
- Surgical Wound
- Surgical Wound Infection
- Teratoma
- Testicular Neoplasms
- Thoracic Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Vaccinia
- Vomiting
- Wilms Tumor
Recent trials (50)
- NCT07284758OfficialPhase 2Jan 31, 2026
- NCT06942442CollaboratorPhase 2Oct 22, 2025
- NCT07002320CollaboratorPhase 1/Phase 2Apr 28, 2025
- NCT06988475CollaboratorPhase 2/Phase 3Nov 19, 2024
- NCT06630260CollaboratorPhase 1/Phase 2Nov 4, 2024
- NCT06632236CollaboratorPhase 1Oct 9, 2024
- NCT06549946OfficialPhase 1/Phase 2Sep 9, 2024
- NCT06560905OfficialPhase 2Sep 1, 2024
- NCT06560905Lead sponsorPhase 2Sep 1, 2024
- NCT06250036Lead sponsorPhase 2Apr 1, 2024
- NCT06068153OfficialPhase 2Mar 31, 2024
- NCT06068153Study chairPhase 2Mar 31, 2024
- NCT05990192Overall official - principal investigatorPhase 2Jan 31, 2024
- NCT05990192CollaboratorPhase 2Jan 31, 2024
- NCT05770544CollaboratorPhase 2/Phase 3Dec 31, 2023
Details
- Founded
- Westminster, GB Jan 1, 1948
- Last known activity
- Jan 31, 2026